·Comparison
Qbrexza vs Sofdra: glycopyrronium tosylate vs sofpironium for excessive underarm sweating
Short answer
Both are FDA-approved once-daily prescription skin treatments that reduce sweating for primary excessive underarm sweating in patients 9+. There is no head-to-head trial; the choice typically depends on dosage-form preference (cloth vs gel), molecule (glycopyrronium vs sofpironium soft-drug), prior tolerability, and prescriber familiarity.
Side-by-side
| Criterion | Qbrexza (glycopyrronium tosylate) | Sofdra (sofpironium) |
|---|---|---|
| Generic molecule | Glycopyrronium tosylate 2.4% | Sofpironium topical gel 12.45% |
| Drug class design | Quaternary-ammonium sweat-reducing medicine | Soft-drug sweat-reducing medicine (rapidly metabolized after whole-body absorption) |
| Dosage form | Single-use pre-moistened cloth | Gel via metered dispenser |
| Frequency | Once daily | Once daily |
| FDA indication | Primary excessive underarm sweating, age 9+ | Primary excessive underarm sweating, age 9+ |
| Pivotal trials | ATMOS-1, ATMOS-2 | CARDIGAN-1, CARDIGAN-2 |
| Primary endpoint | Underarm Sweating Daily Diary (ASDD) responder rate | HDSM-Ax-7 ≥2-point improvement |
| Region applicability | Underarm only | Underarm only |
Which is the better fit when...
- Patient prefers a discrete, travel-friendly dosage form
- Either works; single-use cloth (Qbrexza) is fully self-contained; gel-with-dispenser (Sofdra) has a small footprint but requires the dispenser.
- Patient has had side effects such as dry mouth, constipation, blurred vision, and trouble urinating with prior medications
- Sofdra's soft-drug design is intended to reduce whole-body exposure. Anecdotally some patients tolerate one better than the other; data are not definitive head-to-head.
- Patient has reasons a treatment may not be safe (Sjögren, BPH, glaucoma)
- Both products list sweat-reducing medicine reasons a treatment may not be safe in their labels. Review the prescribing information for the specific product and discuss with the prescribing clinician.
- Insurance coverage drives the choice
- Formulary coverage and cost-after-coverage vary by payer. Many patients consult the prescribing clinician about manufacturer copay-assistance programs available for both products.
Same indication, different molecules
Qbrexza and Sofdra are both prescription skin treatments that reduce sweating approved for the same indication in the same population. The relevant difference is at the molecular and pharmacokinetic level — glycopyrronium tosylate is a quaternary-ammonium that limits whole-body absorption by design, while sofpironium is a soft-drug intended to be rapidly inactivated after whole-body absorption. Both designs aim to deliver limited to certain areas sweat-reducing medicine effect at the application site while limiting whole-body exposure.
No head-to-head trial
There is no published randomized head-to-head trial between Qbrexza and Sofdra. The pivotal trials (ATMOS-1/2 vs CARDIGAN-1/2) used different primary endpoints (ASDD vs HDSM-Ax-7) and different vehicle controls, so cross-trial comparison of response rates is methodologically fraught. Practical choice in clinic typically rests on tolerability, dosage-form preference, and prescriber familiarity.
What's the same
Both products are FDA-approved for primary excessive underarm sweating in patients 9 years and older. Both are once-daily. Both are underarm-only by label. Both can produce sweat-reducing medicine adverse effects (dry mouth, mydriasis if eye contact, urinary hesitation, blurred vision). Both require hand-washing after application to avoid inadvertent eye contact.
Frequently asked
- Can I switch from one to the other?
- Yes — patients sometimes switch when one is inadequately effective or poorly tolerated. There is no required washout. The prescribing clinician determines the timing and counsels on what to expect during the transition.
- Is one safer than the other?
- Both are FDA-approved at their respective doses. The soft-drug design of sofpironium is intended to reduce whole-body exposure, but the practical adverse-event profiles overlap substantially. Specific safety considerations (reasons a treatment may not be safe, drug interactions) are in each product's label.
Read each option in detail
·Related references
Read related evidence.
Treatments compared
Conditions